Samrat Pharmachem Resultados de beneficios anteriores
Pasado controles de criterios 2/6
Samrat Pharmachem has been growing earnings at an average annual rate of 12.7%, while the Chemicals industry saw earnings growing at 15.6% annually. Revenues have been growing at an average rate of 18.9% per year. Samrat Pharmachem's return on equity is 5.6%, and it has net margins of 1.2%.
Información clave
12.7%
Tasa de crecimiento de los beneficios
12.8%
Tasa de crecimiento del BPA
| Crecimiento de la industria Chemicals | 17.7% |
| Tasa de crecimiento de los ingresos | 18.9% |
| Rentabilidad financiera | 5.6% |
| Margen neto | 1.2% |
| Próxima actualización de resultados | 14 Nov 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero Samrat Pharmachem. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 24 | 3,049 | 36 | 22 | 0 |
| 31 Mar 24 | 2,816 | 22 | 24 | 0 |
| 31 Dec 23 | 2,682 | 0 | 23 | 0 |
| 30 Sep 23 | 2,904 | 18 | 22 | 0 |
| 30 Jun 23 | 2,816 | 79 | 20 | 0 |
| 31 Mar 23 | 3,107 | 166 | 21 | 0 |
| 31 Dec 22 | 3,019 | 244 | 30 | 0 |
| 30 Sep 22 | 2,732 | 287 | 29 | 0 |
| 30 Jun 22 | 2,611 | 256 | 43 | 0 |
| 31 Mar 22 | 2,219 | 172 | 18 | 0 |
| 31 Dec 21 | 2,092 | 117 | 23 | 0 |
| 30 Sep 21 | 2,087 | 68 | 21 | 0 |
| 30 Jun 21 | 1,915 | 55 | 34 | 0 |
| 31 Mar 21 | 1,792 | 53 | 18 | 0 |
| 31 Dec 20 | 1,615 | 42 | 27 | 0 |
| 30 Sep 20 | 1,428 | 31 | 30 | 0 |
| 30 Jun 20 | 1,378 | 32 | 30 | 0 |
| 31 Mar 20 | 1,375 | 42 | 15 | 0 |
| 31 Dec 19 | 1,442 | 51 | 15 | 0 |
| 30 Sep 19 | 1,364 | 50 | 15 | 0 |
| 30 Jun 19 | 1,222 | 34 | 14 | 0 |
| 31 Mar 19 | 1,115 | 15 | 15 | 0 |
| 31 Dec 18 | 1,015 | 9 | 14 | 0 |
| 30 Sep 18 | 992 | 21 | 13 | 0 |
| 30 Jun 18 | 974 | 27 | 13 | 0 |
| 31 Mar 18 | 927 | 32 | 14 | 0 |
| 31 Dec 17 | 791 | 27 | 14 | 0 |
| 30 Sep 17 | 721 | 19 | 14 | 0 |
| 30 Jun 17 | 700 | 19 | 13 | 0 |
| 31 Mar 17 | 711 | 18 | 12 | 0 |
| 31 Dec 16 | 781 | 15 | 12 | 0 |
| 30 Sep 16 | 766 | 9 | 13 | 0 |
| 30 Jun 16 | 707 | 5 | 12 | 0 |
| 31 Mar 16 | 619 | 3 | 11 | 0 |
| 31 Dec 15 | 511 | 0 | 22 | 0 |
| 30 Sep 15 | 436 | 0 | 20 | 0 |
| 30 Jun 15 | 460 | 1 | 19 | 0 |
| 31 Mar 15 | 476 | 3 | 10 | 0 |
| 31 Dec 14 | 505 | 7 | 19 | 0 |
| 30 Sep 14 | 591 | 9 | 20 | 0 |
| 30 Jun 14 | 605 | 8 | 21 | 0 |
| 31 Mar 14 | 653 | 2 | 20 | 0 |
| 31 Dec 13 | 701 | -1 | 22 | 0 |
Ingresos de calidad: 530125 has high quality earnings.
Margen de beneficios creciente: 530125's current net profit margins (1.2%) are lower than last year (2.8%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: 530125's earnings have grown by 12.7% per year over the past 5 years.
Acelerando crecimiento: 530125's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Beneficios vs. Industria: 530125 had negative earnings growth (-54.1%) over the past year, making it difficult to compare to the Chemicals industry average (10.4%).
Rentabilidad financiera
Alta ROE: 530125's Return on Equity (5.6%) is considered low.